QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Clinical Program Throughout 2018
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focusing its efforts on immuno-oncology through the development of targeted, safe treatment options for cancer, has been working diligently to advance its clinical program. A recent article discussing the company reads, “The company attained crucial safety and efficacy data via its clinical trials, and it also achieved proof of concept. The phase I/IIa study of its proof of concept clinical trial in advanced breast cancer achieved sustained tumor shrinkage at various sites in several patients. These results confirm the data collected through two previous trials, demonstrating the promising effect of the…